中国人群中肿瘤坏死因子α－308A／G基因多态和α2－巨球蛋白基因缺失多态与晚发性阿尔茨海默病无相关性

晚发性阿尔茨海默病(LOAD)是老年痴呆中最常见的一种,它是一种病因复杂、由遗传因素和环境等其他因素共同作用引起的老年期疾病.服用非甾类抗炎类药物能延缓或防止LOAD的发病说明炎症反应可能参与LOAD病理,肿瘤坏死因子(TNF)是炎症反应中主要的细胞因子,并且能增加β-淀粉样肽(Aβ)的产生说明其可能是LOAD的易感基因.α2-巨球蛋白(A2M)是一种血清蛋白酶抑制剂,它是低密度脂蛋白受体相关蛋白(LRP)主要的配体, 并且能与Aβ结合并介导其降解和清除,说明它可能是另一个LOAD的易感基因.在67名晚发性阿尔茨海默病人和142名正常对照中比较了载脂蛋白E基因 (APOE)、TNF启动子区(-308 A/G)多态和A2M一5 bp核苷酸缺失(I/D)多态(A2M-2)与LOAD发病风险的关系.结果显示,APOE ε4等位基因在AD病人组中显著高于对照组(χ2=11.66,P＜0.01),而TNF(-308 A/G)多态和A2M缺失多态的基因型和等位基因在LOAD病人组和对照组中都无显著差别(P＞0.1).按年龄和APOE ε4等位基因分组同样无相关性,说明TNF-308 A/G位点的多态与A2M缺失不是中国人群的晚发性老年痴呆的风险因子.     

Pathology: Tumor Necrosis Factor in Human Disease

The Scientific Board of the California Medical Association presents the following inventory of items of progress in pathology. Each item, in the judgment of a panel of knowledgeable physicians, has recently become reasonably firmly established, both as to scientific fact and important clinical significance. The items are presented in simple epitome and an authoritative reference, both to the item itself and to the subject as a whole, is generally given for those who may be unfamiliar with a particular item. The purpose is to assist busy practitioners, students, researchers, or scholars to stay abreast of these items of progress in pathology that have recently achieved a substantial degree of authoritative acceptance, whether in their own field of special interest or another.The items of progress listed below were selected by the Advisory Panel to the Section on Pathology of the California Medical Association, and the summaries were prepared under its direction.     

3种人肿瘤坏死因子衍生物的研制

本文在详细分析肿瘤坏死因子（ＴＮＦ）结构的基础上应用ＰＣＲ技术和基因工程手段改造人ＴＮＦ分子,构建了３种人ＴＮＦ的衍生物。３种人ＴＮＦ衍生物是;Ｎ端缺失７个氨基酸且８、９、１０位的ＰｒｏＳｅｒＡｓｐ改为ＡｒｇＬｙｓＡｒｇ的ＴＮＦ（简写为ｈＴＮＦＤ１）：Ｃ端１５７位Ｌｅｕ改为Ｐｈｅ的ＴＮＦ（简写为ｈＴＮＦＤ２）;Ｎ端和Ｃ端同时作上述改变的ＴＮＦ（简写为ｈＴＮＦＤ３）。这３种衍生物在大肠杆菌中均获得较高表述,它们对Ｌ９２９细胞的细胞毒活性较重组天然人ＴＮＦ有很大升高,尤其是ｈＴＮＦＤ１和ｈＴＮＦＤ３,升高达３个数量级。文中对３种衍生物活性升高的原因作了分析。     

肿瘤坏死因子家族及其相关药物的研究进展

细胞凋亡是进化保守的重要生物学过程,具有重要的生理和病理作用,如在免疫系统的发育与稳态以及多种疾病（包括肿瘤）的发 生、发展、预后及治疗等过程中起重要作用。因此,近年来参与细胞凋亡信号转导的肿瘤坏死因子（TNF）/TNF 受体（TNFR）家族的重要 成员TNFα/TNFR、Fas/FasL和TRAIL/TRAILR成为重要的药物靶点,并开发出多个相关靶向药物,尤其是生物药物,其中有些在临床疗 效和商业上获得巨大成功。简介参与细胞凋亡信号转导的TNF/TNFR家族重要成员,着重对其通过介导细胞凋亡而发挥的生物学作用及其 相关药物研发作一综述,希望对我国的药物研发有所裨益。     

重组人肿瘤坏死因子纯化方法的探索

TNF是一种具有多种生物学作用的细胞因子,高纯度TNF的获得是进一步研究其作用机理和探讨防治方法的基础．对克隆后工程菌表达的纯化进行研究,经盐析。透析、离子交换等步骤,成功地制备了高纯度的rhTNF．经SDS－PAGE测定,分子量17kD,纯度＞95％,比活性为3．44×107U／mg,与国外同类产品相似．     

淋巴囊肿病毒中国株TNFR类似物的原核表达与结构分析

肿瘤坏死因子受体(TNFR)是细胞因子受体家族中的一员,在大DNA病毒的免疫逃避中起着重要的作用。 淋巴囊肿病毒中国株(LCDV-C)是一种大DNA病毒,属于虹彩病毒科。参照已知虹彩病毒TNFR基因设计引物: P1,5′GGATCCAAAACTATGATTAAAATAAAGA 3′;P2:5′ATTACTCGAGAATGTTAAAAATTAAGCTT 3′。以LCDV-C基因组DNA为模板,PCR扩增得到一个834bp的DNA片段,并对该片段进行测序。构建原核表 达重组质粒后,在大肠杆菌DE3中诱导表达,其产物经SDS-PAGE电泳后,显示为45kDa的融合蛋白带。对测序 结果进行计算机辅助分析的结果显示,LCDV-C TNFR类似物是一个含278个氨基酸的多肽,具有典型的半胱氨 酸富集区功能结构域,与宿主牙鲆TNFRII氨基酸同源性为34％。     

Development and Characterization of Liposomal Tumor Necrosis Factor (Tnf)

Abstract

Free and liposomal formulations of caprylated TNF-SAM2, a TNF mutant, were evaluated in both a canine model for TNF-induced hypotension and in the murine Meth A sarcoma model for efficacy. The liposomal formulations consisted of caprylated TNF-SAM2 either bound to the outer leaflet of small unilamellar vesicles (SUVs) or encapsulated in multilamellar vesicles (MLVs). Whereas systemic administration of parental TNF-a to anesthesized mongrel dogs resulted in acute shock with a precipitous fall in systemic arterial pressure (SAP), the SUV-TNF-SAM2 resulted in no net hypotension. Both the free and liposomal-TNF-SAM2 elicited a hyperdynamic response with tachycardia and elevated cardiac output and SAP, which was not observed with parental TNF-a. Two tail-vein injections of these formulations were administered 4–5 days apart to BALB/c mice in which Meth A sarcoma cells were previously implanted subcutaneously or intradermally. Free TNF-SAM2 at 4 × 10 U/mouse caused highly significani tumor control compared to PBS on days 5 and 12; however, substantial toxicity (-24% lethality; was observed at this level. The liposomal formulations of caprylated TNF-SAM2 demonstratec significant tumor control at all dose levels (up to 8 × 10 U/mouse) on day 12 (p<0.025) wit! either no or reduced lethality (0–15%); the tumor responses were comparable to those with fret TNF-SAM2. We conclude that the liposomal caprylated-TNF-SAM2 formulations exhibit; therapeutic index superior to that of free parental TNF-a or free TNF-SAM2.     

淋巴囊肿病毒中国株TNFR类似物的原核表达与结构分析

肿瘤坏死因子受体(TNFR)是细胞因子受体家族中的一员,在大DNA病毒的免疫逃避中起着重要的作用.淋巴囊肿病毒中国株(LCDV-C)是一种大DNA病毒,属于虹彩病毒科.参照已知虹彩病毒TNFR基因设计引物P1,5'GGATCCAAAACTATGATTAAAATAAAGA 3';P25'ATTACTCGAGAATGTTAAAAATTAAGCTT3'.以LCDV-C基因组DNA为模板,PCR扩增得到一个834bp的DNA片段,并对该片段进行测序.构建原核表达重组质粒后,在大肠杆菌DE3中诱导表达,其产物经SDS-PAGE电泳后,显示为45kDa的融合蛋白带.对测序结果进行计算机辅助分析的结果显示,LCDV-C TNFR类似物是一个含278个氨基酸的多肽,具有典型的半胱氨酸富集区功能结构域,与宿主牙鲆TNERII氨基酸同源性为34%.     

肿瘤坏死因子家族新成员——TRAIL

肿瘤坏死因子相关的凋亡诱导配体(TRAIL)或称凋亡素2配体(Apo2 ligand, Apo-2L), 是TNF家族的新成员.它是从表达序列标签库(expressed sequenced tag, EST)中寻找TNF的同源分子时发现的.TRAIL是一种分子质量为32.5 ku的Ⅱ型跨膜糖蛋白, 活性形式呈同源三聚体.TRAIL和可溶性的TRAIL强烈诱导肿瘤细胞株凋亡.新近发现的TRAIL受体DR4和DR5及TRID说明了TRAIL与TNF和Fas/Apo-1配体的作用途径是不同的.随着对TRAIL的受体及作用机理研究的深入, TRAIL很可能成为新一代抗肿瘤制剂.     

肿瘤坏死因子受体和配体超家族的新成员

骨原蛋白(OPG)／核因子κB受体激活剂的配体(RANKL)／核因子κB的受体激活剂(RANK)是肿瘤坏死因子受体和配体超家族成员。RANKL由成骨细胞前体／骨髓基质细胞和激活的T淋巴细胞合成,通过结合破骨细胞或树突状细胞表面的RANK受体,促进破骨细胞的形成、融合、激活和存活,并有助于树突状细胞对抗原的提呈作用,OPG作为RANKL的假受体,对此过程具有抑制作用。此外,OPG／RANKL／RANK系统在调节淋巴系统发育、哺乳期动物乳腺腺泡的形成以及大动脉钙化中也起着重要的作用,是一组多功能的细胞因子系统。     

Tumor Necrosis Factor and Lymphotoxin: Molecular Genetics, Regulation and Physiological Role

The data on the regulation of expression and on the biological role of the tumor necrosis factor and lymphotoxin in the author's laboratory, are briefly reviewed in this paper.     

肿瘤坏死因子受体超家族成员在免疫系统和疾病中的研究

肿瘤坏死因子受体超家族 (tumor necrosis factor receptor superfamily, TNFRSF) 是细胞因子受体的一个蛋白质超家族,其显著特征是通过细胞外富含半胱氨酸结构域结合肿瘤坏死因子(tumor necrosis factor,TNF)。肿瘤坏死因子受体(tumor necrosis factor receptors,TNFRs)是古老的细胞因子,TNFRs同源基因最早可追溯到节肢动物果蝇中。TNFRs在炎症反应、细胞凋亡、淋巴细胞稳态和组织发育中发挥重要的作用,TNFRs最主要的功能是与免疫系统相关。鉴于其在免疫系统中发挥重要的作用,肿瘤坏死因子受体家族成员已成为治疗糖尿病、动脉粥样硬化、骨质疏松、自身免疫性疾病、移植排斥反应和癌症等人类疾病的靶点。随着科学技术发展,关于TNFRs的功能有了新的进展,在无脊椎动物和低等脊椎动物中已经有大量报道。在本篇综述中,主要总结了在高等哺乳动物中发现的29种TNFR成员的相关报道,包括8种死亡受体和21种非死亡受体,主要涉及在免疫系统以及与疾病相关领域的研究。大多数研究处于基础实验阶段,少数走向临床研究的案例取得的临床效果并不理想,靶向设计针对自身免疫性疾病、炎症和肿瘤疾病的治疗方案需要更深入的理解TNFRs功能。本文旨在对TNFRs成员发挥的功能有进一步的认识。     

Distinct Pathways for Tumor Necrosis Factor Alpha and Ceramides in Human Cytomegalovirus Infection

Human cytomegalovirus (HCMV) infection can be fatal to immunocompromised individuals. We have previously reported that gamma interferon and tumor necrosis factor alpha (TNF-α) synergistically inhibit HCMV replication in vitro. Ceramides have been described as second messengers induced by TNF-α. To investigate the mechanisms involved in the inhibition of HCMV by TNF-α, in the present study we have analyzed ceramide production by U373 MG astrocytoma cells and the effects of TNF-α versus ceramides on HCMV replication. Our results show that U373 MG cells did not produce ceramides upon incubation with TNF-α. Moreover, long-chain ceramides induced by treatment with exogenous bacterial sphingomyelinase inhibited HCMV replication in synergy with TNF-α. Surprisingly, short-chain permeant C6-ceramide increased viral replication. Our results show that the anti-HCMV activity of TNF-α is independent of ceramides. In addition, our results suggest that TNF-α and endogenous long-chain ceramides use separate pathways of cell signalling to inhibit HCMV replication, while permeant C6-ceramide appears to activate a third pathway leading to an opposite effect.Human cytomegalovirus (HCMV) infections are well controlled in the immunocompetent host. Cellular immune responses (CD4⁺ and CD8⁺ T cells and NK cells) which accompany both acute and latent infections (for a review, see reference 4) are thought to be the main components of this control. HCMV infection during immunosuppression such as in cancer, transplantations, or AIDS results in severe pathology (4). We have previously shown that tumor necrosis factor alpha (TNF-α), in synergy with gamma interferon (IFN-γ), inhibits the replication of HCMV (7). In mice, TNF-α is involved in the clearance of CMV infection (25). TNF-α is a cytokine with multiple effects which is produced by many cell types, including macrophages and CD8⁺ and CD4⁺ T lymphocytes (for a review, see reference 40), and is known to possess antiviral effects (20, 47). The molecular mechanisms involved in the signalling by TNF-α depend on the type of receptor, p55 (TNF-R1) or p75 (TNF-R2) (5), to which it binds. Some cells express only one type of TNF-α receptor; however, expression of these receptors is not always mutually exclusive (5). The cytotoxicity of TNF-α has been reported to be mediated by TNF-R1 (38), whose intracellular region carries a death domain which signals for programmed cell death (39). Signalling through TNF-R1 with specific antibodies can also protect Hep-G2 cells from vesicular stomatitis virus-mediated cytopathic effects (48). Ceramide production after TNF-α treatment has been widely reported (16, 19, 31) and has also been shown to depend on signalling through the TNF-R1 receptor (45). In these experiments concerning myeloid cells, TNF-α induced the activation of a sphingomyelinase, which cleaved sphingomyelin to release ceramide and phosphocholine. The production of ceramides can lead to cell apoptosis (11, 14, 23) or cell cycle arrest (13). Induction of apoptosis by TNF-α has been mimicked by exogenous sphingomyelinase and by synthetic, short-chain, permeant ceramides, which suggests that ceramides, as second messengers, are sufficient to induce the cytotoxic effects of TNF-α (11, 23). Acidic and neutral sphingomyelinases activated in different cell compartments may be responsible for the diverse effects of TNF-α (46), with the former being involved in signalling through NF-κB (34) and the latter being involved in signalling through a ceramide-activated protein kinase and phospholipase A₂ (46).One of the characteristics of HCMV infection is the increase in the content of intracellular DNA, reported to be of viral (3, 8, 18) or cellular (12, 37) origin. Since TNF-α has been known to display antiproliferative properties and to block cells in the G₁ phase (29), we initially tested its effects on the cell cycle of infected cells. Then, based on studies reporting that TNF-α induces ceramides in cells (16, 19, 31) and on a study showing the role of ceramide in cell cycle blockade (13), we originally postulated that ceramide was responsible for the antiviral effect of TNF-α. In the present study, we used astrocytoma cells (U373 MG) as a model for brain cells, which are important targets of HCMV in vivo (22). In contrast to fibroblasts, infected U373 MG cells release smaller quantities of virus particles even though all the cells were infected in our experiments. We believe that the U373 MG model is closer to HCMV infection in vivo. We show that ceramides are not produced by U373 MG cells upon incubation with even high concentrations of TNF-α. In addition, we demonstrate that exogenously added sphingomyelinase induces anti-HCMV effects whereas permeant C6-ceramide increases HCMV proliferation in U373 MG cells. This suggests that lipid second messengers can modulate HCMV infection and that TNF-α and ceramides use distinct signalling pathways in the control of HCMV infection. This is supported by our observation that the protein kinase JNK1 is activated exclusively by TNF-α in U373 MG cells and that TNF-α and exogenous sphingomyelinase act in synergy on HCMV infection.     

Unraveling the Binding Mechanism of Trivalent Tumor Necrosis Factor Ligands and Their Receptors

Characterization of the binding of a tumor necrosis factor (TNF) ligand to its receptor(s) is pivotal to understand how these proteins initiate signal transduction pathways. Unfortunately, kinetic elucidation of these interactions is strongly hampered by the multivalent nature of the binding partners. The interaction between TNF-related apoptosis-inducing ligand and its death receptors was analyzed using in-depth applications of surface plasmon resonance technology. Variations in receptor density and sensor chip type allowed us to manipulate the stoichiometry of the formed complex, and the rate constants describing the binding of trimeric TNF-related apoptosis-inducing ligand to only one receptor molecule were determined. Remarkably, the affinity of this trimer-monomer complex is in the picomolar range, and its dissociation very slow. Further analysis showed that the second and third receptor molecules bind with lower affinity to the preformed trimer-monomer complex. This together with results obtained with receptor activator of NF-κB ligand and B cell-activating factor strongly suggests that the binding of TNF family ligands to their receptors is initiated via the formation of a trimer-monomer complex that is sufficiently stable to allow binding of two additional receptor molecules. These results suggest that avidity does not play a significant role and thus provide new insight in how TNF ligands form the biologically important complexes with their receptors.Cytokines are signaling molecules involved in a range of biological processes and diseases. Cytokines and receptors belonging to the TNF superfamily have been a subject of interest for developing novel therapies for numerous diseases (1). These cytokines e.g. TNFα, TRAIL,1 RANKL, and BAFF are type II transmembrane proteins, and the extracellular C-terminal moiety can be released by specific proteases to form a soluble and active protein consisting of three subunits of each ∼20 kDa (2). As one of the most promising anticancer therapeutic candidates, recombinant human TRAIL (rhTRAIL; comprising amino acids 114–281) is able to kill a variety of cancer cells but not healthy cells. Currently, rhTRAIL is being tested in clinical phase II studies as an anticancer biopharmaceutical (3).Despite good progress on structural insight, analysis of the interactions between TNF ligand family members and their receptors lacks unambiguous results. This seems mainly caused by the multivalent character of these molecules, i.e. trimeric cytokines but also often dimeric receptor-Fc fusions, which lead to complex kinetic behavior. In a series of experiments, we obtained several indications that surface plasmon resonance (SPR) assays with rhTRAIL WT and receptor-specific variants (4–6) offer opportunities to establish a better characterization of their interactions with receptor molecules. For this, we meticulously applied SPR technology to elucidate the dynamics of complex formation of this important group of cytokines. We used rhTRAIL WT; a DR5-specific mutant, rhTRAIL^D269H/E195R; and death receptors DR4 and DR5 to develop the method, but we show with examples of other members of the TNF family that the method is generally applicable. Apart from presenting a method allowing unambiguous affinity determination, our results demonstrate that the binding mechanism of these cytokines is initiated via a high affinity interaction with the first receptor molecule, bringing the cytokine to the membrane.